The product will be marketed and commercialised in the U.S. by Apotex, which is the ANDA applicant, complex peptide-based generics developer Orbicular said in a release.
Source:
www.thehindu.com
Medical Disclaimer:
This content is shared for informational and educational purposes only.
It does not constitute medical, legal, or policy advice.
Healthcare decisions should always be made in consultation with qualified professionals.






